Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET
Company Participants
Lindsey Allen - Head of Investor Relations and Communications
Justin Klee - Co-Chief Executive Officer
Margaret Olinger - Chief Commercial Officer
James Frates - Chief Financial Officer
Josh Cohen - Co-Chief Executive Officer
Conference Call Participants
Corinne Jenkins - Goldman Sachs
Michael DiFiore - Evercore Inc.
Marc Goodman - SVB Securities
Neena Bitritto-Garg - Citigroup Inc.
Ananda Ghosh - H.C. Wainwright & Co.
Operator
Good afternoon. My name is Chuck, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please be advised that this call is being recorded at the company’s request.
I would now like to turn the conference over to Ms. Lindsey Allen, Head of Investor Relations and Communications. Please go ahead, ma’am.
Lindsey Allen
Good afternoon, and thank you for joining us today to discuss our third quarter 2022 earnings. With me on the call are Josh Cohen and Justin Klee are Co-CEOs; Margaret Olinger, our Chief Commercial Officer; and Jim Frates, our Chief Financial Officer.
Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations, and are made pertinent to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements made during this call include our expectations for the commercialization of and the timing of receipt of revenue from RELYVRIO and ALBRIOZA.
Statements regarding regulatory developments, the anticipated timing of coverage and policy decisions by insurance plans related to RELYVRIO and whether those decisions will be favorable. Expectations regarding access to and coverage, our expectations with respect to recruitment and completion of our ongoing PHOENIX trial, and the anticipated ramp in our SG&A expenses. Actual events and results could differ materially from those expressed or implied by any forward-looking statement as a result of various risks, uncertainties and other factors, including most set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements. And Amylyx disclaims any obligation to update such statements.